Drug · CHEMBL660
AMANTADINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMANTADINE. Drugs and targets, record CHEMBL660. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL660
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets7
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| GRIN1 | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/2902 |
| GRIN2A | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/2903 |
| GRIN2B | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/2904 |
| GRIN2C | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/2905 |
| GRIN2D | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/2906 |
| GRIN3A | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/116443 |
| GRIN3B | Glutamate [NMDA] receptor | Glutamate [NMDA] receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/116444 |
Source ChEMBL
Diseases25
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 25Source Open Targets
See all 25 diseasesTrials80
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01227967 | Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications | Phase 2 | 881 | 2017-07-11 | amantadine | Its name | ClinicalTrials.gov |
| NCT03436199 | Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment | Phase 3 | 558 | 2021-12-21 | amantadine | Its name | ClinicalTrials.gov |
| NCT03567057 | A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment | Phase 3 | 424 | 2022-01-18 | amantadine | Its name | ClinicalTrials.gov |
| NCT02202551 | Open-Label Safety Study of ADS-5102 in PD Patients With LID | Phase 3 | 223 | 2020-09-16 | amantadine | Its name | ClinicalTrials.gov |
| NCT00401973 | Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine | Phase 3 | 199 | 2009-09-30 | amantadine | Its name | ClinicalTrials.gov |
| NCT00970944 | Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI) | Phase 2/3 | 184 | 2012-09-24 | amantadine | Its name | ClinicalTrials.gov |
| NCT03185065 | Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis | Phase 3 | 141 | 2020-10-19 | amantadine | Its name | ClinicalTrials.gov |
| NCT02136914 | ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) | Phase 3 | 126 | 2018-02-06 | amantadine | Its name | ClinicalTrials.gov |
| NCT02153645 | Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. | Phase 3 | 87 | 2019-04-02 | amantadine | Its name | ClinicalTrials.gov |
| NCT01397422 | Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) | Phase 2/3 | 83 | 2017-11-06 | amantadine | Its name | ClinicalTrials.gov |
1 to 10 of 80
See all 80 trialsComparisons in its trials19
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Combination Therapy vs Oseltamivir Monotherapy: 28-day Mortality | 0 of 314 | 1 of 312 | 626 | NCT01227967 | Trial comparisons |
| Combination Therapy vs Oseltamivir Monotherapy: deaths from any cause | 0 of 314 | 1 of 312 | 626 | NCT01227967 | Trial comparisons |
| Combination Therapy vs Oseltamivir Monotherapy: serious adverse events | 14 of 314 | 6 of 312 | 626 | NCT01227967 | Trial comparisons |
| Amantadine HCL vs Placebo: serious adverse events | 15 of 87 | 19 of 97 | 184 | NCT00970944 | Trial comparisons |
| ADS-5102 (340 mg) vs Placebo: deaths from any cause | 1 of 63 | 0 of 60 | 123 | NCT02136914 | Trial comparisons |
| ADS-5102 (340 mg) vs Placebo: serious adverse events | 7 of 63 | 3 of 60 | 123 | NCT02136914 | Trial comparisons |
| ADS-5102 (Amantadine HCl Extended Release) vs Placebo: deaths from any cause | 0 of 37 | 0 of 38 | 75 | NCT02274766 | Trial comparisons |
| ADS-5102 (Amantadine HCl Extended Release) vs Placebo: serious adverse events | 4 of 37 | 0 of 38 | 75 | NCT02274766 | Trial comparisons |
| Amantadine vs Placebo: serious adverse events | 0 of 36 | 0 of 32 | 68 | NCT01071395 | Trial comparisons |
| Amantadine vs Placebo: Nausea or Vomiting | 0 of 7 | 0 of 7 | 14 | NCT02486211 | Trial comparisons |
1 to 10 of 19
See all 19 comparisons in its trialsPapers from its trials70
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials5
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Stroop Color-Word Test | 2 | 1 | ConductCognition |
| Symbol Coding | 2 | 0 | ConductCognition |
| Trail Making Test A | 2 | 1 | ConductCognition |
| Verbal Fluency | 2 | 1 | ConductCognition |
| Verbal Learning | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL660
GET https://conductscience.org/api/drugs/v1/CHEMBL660/diseases?page=2